Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.9 USD | -1.49% | -5.29% | -15.50% |
Financials (USD)
Sales 2024 * | 4.05B | Sales 2025 * | 4.36B | Capitalization | 6.65B |
---|---|---|---|---|---|
Net income 2024 * | 430M | Net income 2025 * | 619M | EV / Sales 2024 * | 2.52 x |
Net Debt 2024 * | 3.55B | Net Debt 2025 * | 2.05B | EV / Sales 2025 * | 2 x |
P/E ratio 2024 * |
17.9
x | P/E ratio 2025 * |
11.6
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | -1.67% | ||
1 week | -6.14% | ||
Current month | -6.36% | ||
1 month | -5.44% | ||
3 months | -21.60% | ||
6 months | -14.54% | ||
Current year | -15.69% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 254 M€ | +13.31% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 103.9 | -1.49% | 796 300 |
24-05-22 | 105.5 | -1.36% | 950,129 |
24-05-21 | 107 | -1.52% | 594,542 |
24-05-20 | 108.6 | -0.34% | 604,805 |
24-05-17 | 109 | -1.36% | 574,132 |
Delayed Quote Nasdaq, May 23, 2024 at 03:07 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.69% | 6.65B | |
+38.15% | 723B | |
+34.28% | 595B | |
-4.51% | 369B | |
+20.04% | 332B | |
+2.55% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.10% | 168B |
- Stock Market
- Equities
- JAZZ Stock